ArticleBreast cancer (Dove Medical Press)2026
Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer - A Case Report and Experience-Driven Strategy.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) represents the most frequent female malignancy worldwide, and one of the rare, however life-threatening, complications after oncological treatment is acute myeloid leukemia post cytotoxic therapy (AML-pCT). Moreover, most AML-pCT cases have contributed to previous BC cytotoxic therapies. The treatment approach for AML-pCT in BC survivors with an active second BC represents the challenging decision-making process that is described in this report. Results: A 48-year-old woman was diagnosed with invasive lobular carcinoma of the right breast (T2N0M0, Conclusion: In this case report, we describe the therapeutic success of intensive alloHCT in AML-pCT patient with active BC. The presented treatment approach for active BC and AML-pCT requires collaboration between oncologists and hematologists to ensure fast decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.